Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Viral Vector Manufacturing Industry By 2029?

The market size for viral vector manufacturing has seen a swift increase in recent years. Rising from a valuation of $6.93 billion in 2024, it is anticipated to reach $8.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 19.1%. Factors contributing to this significant growth during the historic period include the expansion of gene therapy pipelines, successful clinical trials and approvals, heightened investment in biopharmaceuticals, and a higher occurrence of genetic disorders.

The market size for viral vector manufacturing is projected to undergo significant expansion in the coming years, with a forecasted valuation of $17.42 billion in 2029, reflecting a compound annual growth rate (CAGR) of 20.5%. The expanse in this market through the forecast period can be linked to an increase in its usage in oncology, global partnerships in gene therapy research, the implementation of viral vectors in the development of vaccines, ongoing clinical trials, and commercialization. The forecast period is expected to see major fluctuations in trends such as technological advances in vector production, the emergence of next-generation vectors, adherence to regulatory norms, collaborations and partnerships, and a worldwide expansion in manufacturing facilities.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Are The Primary Factors Supporting The Viral Vector Manufacturing Market Expansion?

The escalation in the occurrence of cancer and infectious diseases is anticipated to spur the advancement of the viral vector manufacturing market. An infectious disease, caused by a virus or its harmful byproduct, can spread to a vulnerable host through contact with an infected individual, creature, or object. Cancer is an umbrella term for a variety of diseases that can occur in any part of the body when rogue cells multiply out of control, invade nearby body parts, and metastasize to other organs. Tumor antigens, or proteins on cancer cells, are created using viral vectors to trigger the body’s immune response against cancer. Viral vectors have been utilized as vaccines against a range of infectious diseases in both pre-clinical and clinical trials. For example, as per the Australian Institute of Health and Welfare, a government agency based in Australia, the number of diagnosed cancer cases escalated from 160,570 in 2022 to 164,694 in 2023, marking a significant increase year-over-year in July 2024, directing to an upward pattern in the incidence of cancer. Additionally, England saw a near sevenfold increase in the number of measles cases, from 53 in 2022 to 368 in 2023, as reported by the UK Health Security Agency. The West Midlands and London were responsible for 44% and 33% of these cases, respectively, according to data released by the UK-based executive agency in August 2024. Hence, the escalation in cancer and infectious disease cases is propelling the growth of the viral vector manufacturing market.

Which Segmentation Factors Are Critical In The Viral Vector Manufacturing Market Analysis?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

What Are The Dominant Trends Currently Seen In The Viral Vector Manufacturing Market?

The rise of product innovation is a notable trend emerging in the viral vector manufacturing market. To maintain their competitive position, major companies within the market are leaning towards innovative product introductions. Take for example Merck KGaA, a science and technology firm based in Germany, which in August 2022 debuted the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. As one of the inaugural Contract development and manufacturing organizations and technology contributors, they provide a complete viral vector manufacturing package covering AAV, Lentiviral, CDMO, CTO, and process development. This innovative platform aids biopharmaceutical firms in reducing process development duration and costs while boosting the speed of their clinical manufacturing.

Which Companies Hold A Competitive Edge In The 239 Market?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Region Is Leading Innovation In The Viral Vector Manufacturing Market?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model